E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors

LESSONS LEARNED. Rate of progression‐free survival at a particular point in time, i.e., a landmark analysis, is a difficult endpoint for a heterogenous malignancy such as neuroendocrine cancer. Landmark analyses can also be complicated by evolution in the standard of care during the conduct of a cli...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Lubner, Sam, Feng, Yang, Mulcahy, Mary, O'Dwyer, Peter, Giang, Guang‐Yu, Hinshaw, J. Louis, Deming, Dustin, Klein, Leonard, Teitelbaum, Ursina, Payne, Jennifer, Engstrom, Paul, Stella, Philip, Meropol, Neal, Benson, Al
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192662/
https://ncbi.nlm.nih.gov/pubmed/29853660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0294
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados